The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
In this inaugural episode of Myeloid Monthly, host Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, is joined by hematopathology experts Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, reporting from the Classification Advancement Meeting (CAM) in Chicago, IL. This is a landmark effort to harmonize the two competing myeloid malignancy classification systems, the WHO and ICC, which diverged in 2022. The experts break down why accurate disease classification matters for patient care, clinical trial enrollment, and drug development, and explore how the field has evolved from morphology-based diagnosis toward molecularly defined disease entities across myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and MDS/myeloproliferative neoplasm (MPN) overlap syndromes. The CAM represents years of expert working group discussions aimed at producing unified recommendations that will inform the next official WHO classification. This webinar took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
